治疗前原发肿瘤体积作为头颈癌放化疗预后因素的外部验证
研究利用RADCURE数据集,以Cox回归分析原发肿瘤体积(GTVp)与局部失败、无进展生存(PFS)和总生存(OS)的关联,在1286例口咽鳞癌(OPSCC)中验证GTVp增大与局部失败风险升高及PFS、OS降低相关,且该关联在HPV状态和化疗亚组中一致,下咽癌(n=157)和喉癌(n=803)也观察到类似关联,模型性能较强(C-index最高0.82)。
要点
- GTVp增大与OPSCC局部失败风险升高及PFS、OS降低相关。
- 该预后关联在HPV状态和化疗亚组中一致。
- 下咽癌和喉癌中也观察到GTVp与预后的类似关联。
核心结论
- 原发肿瘤体积是头颈癌各部位稳健的预后因素,支持根治性放疗中的风险分层。
研究设计与样本
- 外部验证研究,分析RADCURE数据集中的患者,采用Cox回归评估局部失败、PFS和OS,并按HPV状态、化疗使用及下咽癌和喉癌分别进行亚组分析,模型性能用C-index评估。
主要发现
- 在1286例OPSCC患者中,GTVp增大与局部失败风险升高及PFS和OS降低相关,且在HPV和化疗亚组中一致。
- 下咽癌(n=157)和喉癌(n=803)中也观察到类似的关联。
- 模型性能较强,C-index最高达0.82。
关键数值与推荐
- OPSCC患者1286例,下咽癌157例,喉癌803例;C-index最高0.82。
临床怎么用
- 可将治疗前原发肿瘤体积用于头颈癌根治性放疗的风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary tumor volume (GTVp) is a key prognostic factor in oropharyngeal squamous cell carcinoma (OPSCC) treated with radiotherapy. We aimed to externally validate this association and assess its relevance in other head and neck sites. METHODS: Patients from the RADCURE dataset were analyzed using Cox regression for local failure, progression-free survival (PFS), and overall survival (OS). Subgroup analyses included HPV status, chemotherapy use, and separate evaluations for hypopharyngeal and laryngeal cancers. Model performance was assessed using the concordance index (C-index). RESULTS: Among 1286 OPSCC patients, increasing GTVp was associated with a higher risk of local failure and reduced PFS and OS, consistent across HPV and chemotherapy subgroups. Similar associations were observed in hypopharyngeal (n = 157) and laryngeal (n = 803) cancers. Model performance was strong (C-index up to 0.82). CONCLUSION: Primary tumor volume is a robust prognostic factor across head and neck cancer sites, supporting risk stratification in curative radiotherapy.
引用
- Adrian G, Änghede AH, McDowell L, et al. External Validation of Pre-Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy. Head Neck. 2026. PMID: 42115128. doi:10.1002/hed.70315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。